Phase I trial of ONO 7268MX1 in patients with hepatocellular carcinoma (liver cancer) who are refractory or intolerant to standard therapy.
Phase of Trial: Phase I
Latest Information Update: 20 Jan 2018
At a glance
- Drugs ONO-7268MX1 (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
- 20 Jan 2018 Results assessing tolerability of ONO-7268MX1 presented at the 2018 Gastrointestinal Cancers Symposium
- 15 Jul 2016 Status changed from not yet recruiting to completed.
- 02 Jun 2016 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information JapicCTI121933).